PT  - JOURNAL ARTICLE
AU  - PANDE, AMITKUMAR
AU  - LOMBARDO, JEFFREY
AU  - SPANGENTHAL, EDWARD
AU  - JAVLE, MILIND
TI  - Hypertension Secondary to Anti-angiogenic Therapy: Experience with Bevacizumab
DP  - 2007 Sep 01
TA  - Anticancer Research
PG  - 3465--3470
VI  - 27
IP  - 5B
4099  - http://ar.iiarjournals.org/content/27/5B/3465.short
4100  - http://ar.iiarjournals.org/content/27/5B/3465.full
SO  - Anticancer Res2007 Sep 01; 27
AB  - Background: Hypertension (HT) is a common complication of anti-angiogenic therapy. Its incidence, treatment and complications are undefined. Patients and Methods: Retrospective review of patients treated with bevacizumab (BV) from 2003-5. Common toxicity criteria (CTC) for adverse events version 3.0 were used. Results: Fifty-five out of the 154 patients treated with BV (35%) experienced HT. Eleven (20%) developed a new onset HT and 44 (80%) experienced an exacerbation of pre-existing HT. HT developed after a median of 11 weeks at a median BV dose of 10 mg/kg. HT severity was grade 1 (n=1), grade 2 (n=29) or grade 3 (n=22); 3 experienced hypertensive complications. HT was controlled in 47 (85%); BV was discontinued in 3. The angiotensin-converting enzyme inhibitor (ACE-I), quinapril was commonly used and resulted in better HT control than ACE-II, calcium channel or beta antagonists. Conclusion: HT associated with bevacizumab therapy is a manageable toxicity with the use of ACE-I. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved